Novo Nordisk said on Oct. 19 that China’s National Medical Products
Administration (NMPA) has approved an update to product information for its
semaglutide injection, allowing the unopened product to be stored at 2°C–30°C
for up to 48 hours during distribution to patients prior to first use. Novo
Nordisk said this makes the product the first and only GLP-1 weight-management
therapy in China with this delivery flexibility.